Litcius/Paper detail

Transferrable protection by gut microbes against STING-associated lung disease

Derek J. Platt, Dylan Lawrence, Rachel Rodgers, Lawrence A. Schriefer, Wei Qian, Cathrine A. Miner, Amber M. Menos, Elizabeth A. Kennedy, Stefan T. Peterson, William A. Stinson, Megan T. Baldridge, Jonathan J. Miner

2021Cell Reports22 citationsDOIOpen Access PDF

Abstract

STING modulates immunity by responding to bacterial and endogenous cyclic dinucleotides (CDNs). Humans and mice with STING gain-of-function mutations develop a syndrome known as STING-associated vasculopathy with onset in infancy (SAVI), which is characterized by inflammatory or fibrosing lung disease. We hypothesized that hyperresponsiveness of gain-of-function STING to bacterial CDNs might explain autoinflammatory lung disease in SAVI mice. We report that depletion of gut microbes with oral antibiotics (vancomycin, neomycin, and ampicillin [VNA]) nearly eliminates lung disease in SAVI mice, implying that gut microbes might promote STING-associated autoinflammation. However, we show that germ-free SAVI mice still develop severe autoinflammatory disease and that transferring gut microbiota from antibiotics-treated mice to germ-free animals eliminates lung inflammation. Depletion of anaerobes with metronidazole abolishes the protective effect of the VNA antibiotics cocktail, and recolonization with the metronidazole-sensitive anaerobe Bacteroides thetaiotaomicron prevents disease, confirming a protective role of a metronidazole-sensitive microbe in a model of SAVI.

Topics & Concepts

StingMetronidazoleAntibioticsLungDiseaseClindamycinImmunologyBiologyMicrobiologyMedicineInternal medicineAerospace engineeringEngineeringRespiratory viral infections researchBacteriophages and microbial interactionsClostridium difficile and Clostridium perfringens research
Transferrable protection by gut microbes against STING-associated lung disease | Litcius